Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
Tardive akathisia (TA) is a well-documented side-effect of neuroleptic treatment. The underlying mechanism is poorly understood, and treatment is unsatisfactory. In this case report, TA that occurred in the course of a tardive dyskinesia (TD) was successfully treated with the monoamine-oxidase-A inhibitor moclobemide. With respect to the mechanism of action, it may be hypothesized that dopaminergic supersensitivity in the mesocortical region is counteracted by enhanced inhibition of primarily noradrenergic neurotransmission.
Ebert
D
D
Department of Psychiatry, University of Erlangen-Nürnberg, Germany.
Demling
J
J
D017109:Akathisia, Drug-Induced; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D011595:Psychomotor Agitation / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide